S&P 500   3,832.90 (-0.22%)
DOW   30,838.46 (-0.51%)
QQQ   325.75 (+0.10%)
AAPL   141.63 (+1.84%)
MSFT   226.34 (+0.17%)
FB   275.04 (+0.20%)
GOOGL   1,871.52 (-1.11%)
AMZN   3,281.00 (-0.34%)
TSLA   865.81 (+2.26%)
NVDA   538.17 (-1.88%)
BABA   259.60 (+0.38%)
CGC   32.77 (-3.05%)
GE   10.88 (-2.07%)
MU   79.73 (-3.10%)
AMD   92.83 (+0.04%)
NIO   59.94 (-3.24%)
T   28.85 (-0.28%)
F   10.99 (-4.60%)
ACB   10.16 (-4.60%)
BA   200.46 (-2.61%)
DIS   170.23 (-1.48%)
NFLX   556.14 (-1.60%)
GILD   67.01 (+0.10%)
S&P 500   3,832.90 (-0.22%)
DOW   30,838.46 (-0.51%)
QQQ   325.75 (+0.10%)
AAPL   141.63 (+1.84%)
MSFT   226.34 (+0.17%)
FB   275.04 (+0.20%)
GOOGL   1,871.52 (-1.11%)
AMZN   3,281.00 (-0.34%)
TSLA   865.81 (+2.26%)
NVDA   538.17 (-1.88%)
BABA   259.60 (+0.38%)
CGC   32.77 (-3.05%)
GE   10.88 (-2.07%)
MU   79.73 (-3.10%)
AMD   92.83 (+0.04%)
NIO   59.94 (-3.24%)
T   28.85 (-0.28%)
F   10.99 (-4.60%)
ACB   10.16 (-4.60%)
BA   200.46 (-2.61%)
DIS   170.23 (-1.48%)
NFLX   556.14 (-1.60%)
GILD   67.01 (+0.10%)
S&P 500   3,832.90 (-0.22%)
DOW   30,838.46 (-0.51%)
QQQ   325.75 (+0.10%)
AAPL   141.63 (+1.84%)
MSFT   226.34 (+0.17%)
FB   275.04 (+0.20%)
GOOGL   1,871.52 (-1.11%)
AMZN   3,281.00 (-0.34%)
TSLA   865.81 (+2.26%)
NVDA   538.17 (-1.88%)
BABA   259.60 (+0.38%)
CGC   32.77 (-3.05%)
GE   10.88 (-2.07%)
MU   79.73 (-3.10%)
AMD   92.83 (+0.04%)
NIO   59.94 (-3.24%)
T   28.85 (-0.28%)
F   10.99 (-4.60%)
ACB   10.16 (-4.60%)
BA   200.46 (-2.61%)
DIS   170.23 (-1.48%)
NFLX   556.14 (-1.60%)
GILD   67.01 (+0.10%)
S&P 500   3,832.90 (-0.22%)
DOW   30,838.46 (-0.51%)
QQQ   325.75 (+0.10%)
AAPL   141.63 (+1.84%)
MSFT   226.34 (+0.17%)
FB   275.04 (+0.20%)
GOOGL   1,871.52 (-1.11%)
AMZN   3,281.00 (-0.34%)
TSLA   865.81 (+2.26%)
NVDA   538.17 (-1.88%)
BABA   259.60 (+0.38%)
CGC   32.77 (-3.05%)
GE   10.88 (-2.07%)
MU   79.73 (-3.10%)
AMD   92.83 (+0.04%)
NIO   59.94 (-3.24%)
T   28.85 (-0.28%)
F   10.99 (-4.60%)
ACB   10.16 (-4.60%)
BA   200.46 (-2.61%)
DIS   170.23 (-1.48%)
NFLX   556.14 (-1.60%)
GILD   67.01 (+0.10%)
Log in
NASDAQ:IDXX

IDEXX Laboratories Stock Forecast, Price & News

$486.27
-6.59 (-1.34 %)
(As of 01/25/2021 12:20 PM ET)
Add
Compare
Today's Range
$482.53
Now: $486.27▼
$495.96
50-Day Range
$449.88
MA: $485.67▼
$513.20
52-Week Range
$168.65
Now: $486.27▼
$516.86
Volume6,370 shs
Average Volume380,636 shs
Market Capitalization$41.48 billion
P/E Ratio84.72
Dividend YieldN/A
Beta0.88
IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
IDEXX Laboratories logo

MarketRank™

Overall MarketRank™

1.46 out of 5 stars

Medical Sector

469th out of 1,923 stocks

Diagnostic Substances Industry

10th out of 32 stocks

Analyst Opinion: 1.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:IDXX
Previous Symbol
CUSIP45168D10
CIK874716
Webwww.idexx.com
Phone207-556-0300
Employees9,200
Year FoundedN/A

Debt

Debt-to-Equity Ratio1.93
Current Ratio1.65
Quick Ratio1.24

Price-To-Earnings

Trailing P/E Ratio84.72
Forward P/E Ratio79.33
P/E Growth4.55

Sales & Book Value

Annual Sales$2.41 billion
Price / Sales17.23
Cash Flow$5.88 per share
Price / Cash Flow82.76
Book Value$2.07 per share
Price / Book234.91

Profitability

EPS (Most Recent Fiscal Year)$4.89
Net Income$427.72 million
Net Margins19.20%
Return on Equity198.91%
Return on Assets25.75%

Miscellaneous

Outstanding Shares85,300,000
Market Cap$41.48 billion
Next Earnings Date2/2/2021 (Confirmed)
OptionableOptionable
$486.27
-6.59 (-1.34 %)
(As of 01/25/2021 12:20 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IDXX News and Ratings via Email

Sign-up to receive the latest news and ratings for IDXX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











IDEXX Laboratories (NASDAQ:IDXX) Frequently Asked Questions

How has IDEXX Laboratories' stock price been impacted by COVID-19 (Coronavirus)?

IDEXX Laboratories' stock was trading at $245.58 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, IDXX shares have increased by 102.0% and is now trading at $495.96.
View which stocks have been most impacted by COVID-19.

Is IDEXX Laboratories a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IDEXX Laboratories stock.
View analyst ratings for IDEXX Laboratories or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than IDEXX Laboratories?

Wall Street analysts have given IDEXX Laboratories a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but IDEXX Laboratories wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Jay Mazelsky's approval rating as IDEXX Laboratories' CEO?

40 employees have rated IDEXX Laboratories CEO Jay Mazelsky on Glassdoor.com. Jay Mazelsky has an approval rating of 69% among IDEXX Laboratories' employees.

When is IDEXX Laboratories' next earnings date?

IDEXX Laboratories is scheduled to release its next quarterly earnings announcement on Tuesday, February 2nd 2021.
View our earnings forecast for IDEXX Laboratories.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced its quarterly earnings data on Thursday, October, 29th. The company reported $1.69 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.42 by $0.27. The firm had revenue of $721.79 million for the quarter, compared to analysts' expectations of $672.48 million. IDEXX Laboratories had a net margin of 19.20% and a trailing twelve-month return on equity of 198.91%. IDEXX Laboratories's quarterly revenue was up 19.2% compared to the same quarter last year. During the same period in the previous year, the business posted $1.24 EPS.
View IDEXX Laboratories' earnings history.

How will IDEXX Laboratories' stock buyback program work?

IDEXX Laboratories announced that its Board of Directors has approved a share buyback plan on Wednesday, February 12th 2020, which authorizes the company to repurchase 5,000,000 shares, according to EventVestor. This repurchase authorization authorizes the company to buy shares of its stock through open market purchases. Shares repurchase plans are typically an indication that the company's board of directors believes its shares are undervalued.

What price target have analysts set for IDXX?

3 Wall Street analysts have issued 12 month price objectives for IDEXX Laboratories' shares. Their forecasts range from $375.00 to $422.00. On average, they expect IDEXX Laboratories' stock price to reach $395.67 in the next twelve months. This suggests that the stock has a possible downside of 20.2%.
View analysts' price targets for IDEXX Laboratories or view Wall Street analyst' top-rated stocks.

Are investors shorting IDEXX Laboratories?

IDEXX Laboratories saw a decrease in short interest during the month of December. As of December 31st, there was short interest totaling 684,500 shares, a decrease of 16.8% from the December 15th total of 823,100 shares. Based on an average daily volume of 400,800 shares, the short-interest ratio is currently 1.7 days. Currently, 0.8% of the shares of the stock are short sold.
View IDEXX Laboratories' Short Interest.

Who are some of IDEXX Laboratories' key competitors?

Some companies that are related to IDEXX Laboratories include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), Hologic (HOLX), Insulet (PODD), Teleflex (TFX), STERIS (STE) and Varian Medical Systems (VAR).
View all of IDXX's competitors.

What other stocks do shareholders of IDEXX Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), PayPal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA), Alibaba Group (BABA), Square (SQ), The Walt Disney (DIS) and Shopify (SHOP).

Who are IDEXX Laboratories' key executives?

IDEXX Laboratories' management team includes the following people:
  • Mr. Jonathan J. Mazelsky, Pres, CEO & Director (Age 60, Pay $1.62M)
  • Ms. Sharon E. Underberg, Exec. VP, CFO & Treasurer (Age 60, Pay $809.42k)
  • Ms. Kathy V. Turner, Chief Marketing Officer & Corp. VP (Age 57, Pay $1.95M)
  • Mr. Jonathan W. Ayers, Sr. Advisor & Director (Age 65, Pay $3.2M)
  • Mr. Michael J. Lane, Exec. VP and GM of Reference Laboratories & Information Technology (Age 53, Pay $724.02k)
  • Mr. John Hart, Corp. VP of Worldwide Operations
  • Mr. Jeffery D. Chadbourne, Sr. Director of Accounting & Financial Reporting (Age 45)
  • Mr. Jeffrey Thomas, Corp. VP & Chief Technology Officer
  • Mr. Ken Grady, Corp. VP & Chief Information Officer
  • Ms. Kerry Bennett, VP of Investor Relations

What is IDEXX Laboratories' stock symbol?

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

Who are IDEXX Laboratories' major shareholders?

IDEXX Laboratories' stock is owned by many different institutional and retail investors. Top institutional investors include Frontier Capital Management Co. LLC (0.25%), Welch & Forbes LLC (0.21%), Manning & Napier Group LLC (0.19%), Loring Wolcott & Coolidge Fiduciary Advisors LLP MA (0.17%), Riverbridge Partners LLC (0.16%) and Ardevora Asset Management LLP (0.12%). Company insiders that own IDEXX Laboratories stock include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, Jacqueline Studer, James F Polewaczyk, Jay Mazelsky, Jonathan Jay Mazelsky, Jonathan W Ayers, Lawrence D Kingsley, M Anne Szostak, Michael Lane, Nimrata Hunt, Rebecca M Henderson and Sophie V Vandebroek.
View institutional ownership trends for IDEXX Laboratories.

Which institutional investors are selling IDEXX Laboratories stock?

IDXX stock was sold by a variety of institutional investors in the last quarter, including Ardevora Asset Management LLP, Candriam Luxembourg S.C.A., Baldwin Brothers Inc. MA, Pacer Advisors Inc., Gateway Investment Advisers LLC, Welch & Forbes LLC, MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH, and Cacti Asset Management LLC. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, James F Polewaczyk, Jonathan Jay Mazelsky, Jonathan W Ayers, M Anne Szostak, Michael Lane, Nimrata Hunt, and Rebecca M Henderson.
View insider buying and selling activity for IDEXX Laboratories or view top insider-selling stocks.

Which institutional investors are buying IDEXX Laboratories stock?

IDXX stock was acquired by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, Frontier Capital Management Co. LLC, DNB Asset Management AS, Riverbridge Partners LLC, Louisiana State Employees Retirement System, LGT Capital Partners LTD., Kestra Advisory Services LLC, and Crossmark Global Holdings Inc..
View insider buying and selling activity for IDEXX Laboratories or or view top insider-buying stocks.

How do I buy shares of IDEXX Laboratories?

Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is IDEXX Laboratories' stock price today?

One share of IDXX stock can currently be purchased for approximately $495.96.

How big of a company is IDEXX Laboratories?

IDEXX Laboratories has a market capitalization of $42.31 billion and generates $2.41 billion in revenue each year. The company earns $427.72 million in net income (profit) each year or $4.89 on an earnings per share basis. IDEXX Laboratories employs 9,200 workers across the globe.

What is IDEXX Laboratories' official website?

The official website for IDEXX Laboratories is www.idexx.com.

How can I contact IDEXX Laboratories?

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]

This page was last updated on 1/25/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.